HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masayuki Senda Selected Research

Masayuki Senda Research Topics

Disease

8Type 2 Diabetes Mellitus (MODY)
02/2021 - 09/2016
7Diabetes Mellitus
02/2021 - 09/2019
5Drug-Related Side Effects and Adverse Reactions
02/2021 - 09/2016
3Hypoglycemia (Reactive Hypoglycemia)
02/2021 - 01/2020
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
02/2021
1Weight Loss (Weight Reduction)
07/2020
1Urinary Tract Infections (Urinary Tract Infection)
10/2017
1Body Weight (Weight, Body)
10/2017

Drug/Important Bio-Agent (IBA)

106- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
02/2021 - 09/2016
6Glucose (Dextrose)FDA LinkGeneric
07/2020 - 09/2016
5Insulin (Novolin)FDA Link
02/2021 - 10/2017
5SodiumIBA
07/2020 - 09/2016
4Insulin Glargine (Lantus)FDA Link
02/2021 - 01/2017
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
02/2021 - 07/2020
2SymportersIBA
10/2017 - 09/2016
1Hypoglycemic Agents (Hypoglycemics)IBA
03/2020
1Glucagon-Like Peptide-1 ReceptorIBA
11/2019
1SolutionsIBA
01/2018
1Sodium-Glucose Transport ProteinsIBA
11/2017
1Sodium-Glucose Transporter 2 InhibitorsIBA
10/2017
1Uric Acid (Urate)IBA
10/2017
1lixisenatideIBA
01/2017
1Sitagliptin Phosphate (Januvia)FDA Link
01/2017

Therapy/Procedure

3Therapeutics
09/2019 - 10/2017